Development of cebranopadol, a potent dual MOP/NOP agonist, for the treatment of Opioid Use Disorder (OUD)

The objective of the project is the clinical development of Cebranopadol for the treatment of opioid addiction. The project may be funded by the NIH-NIDA, and the study will be conducted in collaboration with Park Therapeutics, the company that holds the property rights to the molecule.

Identification of a molecular scaffold for the development of a PET tracer for purinergic P2X7 receptor for molecular imaging of neuroinflammation in PD

Neuroinflammation plays a pivotal role in the pathogenesis of neurodegeneration in Parkinson's Disease (PD) through the upregulation of proinflammatory factors and microglia activation. The purinergic P2X7 receptor (P2X7R) is among the targets actively investigated as PET biomarkers of neuroinflammation because of its crucial role in microglia activation and expression associated with

The role of PKCd in Opioid Use Disorders

Questo progetto riguarda lo studio del ruolo dell´amigdala centrale ed il gene PKCD nell´uso compulsivo dell´eroina. Per la realizzazione di questo progetto lè stata importata dalla Svezia una linea di ratti transgenici "Prkcd Cre Knock in" presso lo stabulario della Scuola del Farmaco, dove il gene PKCD verra´ manipolato attraverso degli approcci virali per testarne il suo ruolo in un modello preclinico di consumo compulsivo di eroina.